Boothbay Fund Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-183,522
| Closed | -$7.38M | – | 2235 |
|
|
2026
Q1 | $7.38M | Buy |
183,522
+162,107
| +757% | +$3.49M | 0.1% | 208 |
|
|
2025
Q4 | $538K | Sell |
21,415
-157,811
| -88% | -$3.7M | 0.01% | 1094 |
|
|
2025
Q3 | $4.06M | Buy |
179,226
+156,229
| +679% | +$3.64M | 0.06% | 366 |
|
|
2025
Q2 | $398K | Hold |
22,997
| – | – | 0.01% | 1000 |
|
|
2025
Q1 | $503K | Buy |
+22,997
| New | +$635K | 0.01% | 850 |
|
|
2024
Q2 | – | Sell |
-24,825
| Closed | -$1.46M | – | 1503 |
|
|
2024
Q1 | $1.46M | Buy |
24,825
+12,169
| +96% | +$776K | 0.03% | 614 |
|
|
2023
Q4 | $758K | Buy |
12,656
+4,806
| +61% | +$244K | 0.02% | 816 |
|
|
2023
Q3 | $299K | Sell |
7,850
-19,344
| -71% | -$850K | 0.01% | 1249 |
|
|
2023
Q2 | $2.48M | Buy |
27,194
+6,136
| +29% | +$529K | 0.05% | 473 |
|
|
2023
Q1 | $1.39M | Buy |
+21,058
| New | +$1.22M | 0.03% | 842 |
|
|
2022
Q3 | – | Sell |
-5,065
| Closed | -$300K | – | 2223 |
|
|
2022
Q2 | $229K | Buy |
+5,065
| New | +$231K | 0.01% | 1644 |
|
|
2021
Q4 | – | Sell |
-34,671
| Closed | -$1.36M | – | 1842 |
|
|
2021
Q3 | $1.14M | Buy |
+34,671
| New | +$1.95M | 0.03% | 699 |
|
|
2020
Q2 | – | Sell |
-9,448
| Closed | -$253K | – | 952 |
|
|
2020
Q1 | $253K | Buy |
+9,448
| New | +$335K | 0.02% | 610 |
|
|
2019
Q1 | – | Sell |
-26,000
| Closed | -$343K | – | 741 |
|
|
2018
Q4 | $343K | Buy |
+26,000
| New | +$399K | 0.05% | 353 |
|
Other funds holding APLS
Boothbay Fund Management's APLS Position: Q2 2026 in Review
Boothbay Fund Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 183,522 shares — an estimated $7.38M sold.
Boothbay Fund Management first reported a position in APLS in Q4 2018 and held it in 14 quarters. The position peaked at $7.38M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Boothbay Fund Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Boothbay Fund Management sold 183,522 Apellis Pharmaceuticals shares in Q2 2026, an estimated $7.38M.
- Boothbay Fund Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 14 quarters.
- Boothbay Fund Management's Apellis Pharmaceuticals position peaked at $7.38M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.